Atorvastatin Versus Revascularization Treatment (AVERT): Fact or fancy?

American Heart Journal

Volumn 140, Issue 1, 2000, Pages 6-9

  Singh, Balkrishna M ^a   Puri, Sanjeev ^a   Saucedo, Jorge ^a   Talley, J David ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CHOLESTEROL; FIBRINOGEN RECEPTOR ANTAGONIST; LOW DENSITY LIPOPROTEIN;

ANGIOPLASTY; CORONARY ARTERY DISEASE; DISEASE COURSE; EDITORIAL; HEART MUSCLE REVASCULARIZATION; INTERMETHOD COMPARISON; MEDICAL RESEARCH; METHODOLOGY; MORTALITY; PATIENT SELECTION; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM;

EID: 0033914004     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2000.106912     Document Type: Article

References (29)

1. Pitt B, Waters D, Brown WV. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment investigators. N Engl J Med. 341:1999;70-76.
2. Lancet. 350:1997;461-468.
3. O'Keffe JHJ, Bateman TM, Ligon RW. Outcome of medical versus invasive treatment strategies for non-high-risk ischemic heart disease. J Nucl Cardiol. 5:1998;28-33.
4. European Coronary, Surgery Study. Long-term results of prospective randomized study of coronary artery bypass surgery in stable angina pectoris. Lancet. 2:1982;1173-1180.
5. Circulation. 86:1992;121-130.
6. Alderman EL, Bourassa MG, Cohen LS. Ten year follow-up of survival and myocardial infarction in the randomized Coronary Artery Surgery Study. Circulation. 82:1990;1629-1646.
7. Parisi AF, Folland ED, Hartigan P, on behalf of the Veterans Affairs, ACME investigators. A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. N Engl J Med. 326:1992;10-16.
8. Hueb WA, Bellotti G, deOliveria SA. The Medicine, Angioplasty or Surgery (MASS): a prospective randomized trial of medical therapy, balloon angioplasty or bypass surgery for single proximal left anterior descending artery stenosis. J Am Coll Cardiol. 26:1995;1600-1605.
9. Johnson RG, Sirois C, Thurer RL. Predictors of CABG within one year of successful PTCA: a retrospective, case control study. Ann Thorac Surg. 64:1997;3-8.
10. Lincoff M, Califf RM, Moliterno DJ. Complimentary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. N Engl J Med. 341:1999;319-327.
11. Jones RH, Kesler K, Phillips HR. Long-term survival benefits of coronary artery bypass grafting and percutaneous transluminal angioplasty in patients with coronary artery disease. J Thorc Cardiovasc Surg. 111:1996;1013-1025.
12. Myers WO, Schaff HV, Fisher LD. Time to first new myocardial infarction in patients with severe angina and three vessel disease comparing medical and early surgical therapy: a CASS registry study of survival. J Thorac Cardiovasc Surg. 95:1988;382-389.
13. Muhlbaier L, Pryor D, Rankin J. Observational comparison of event free survival with medical and surgical therapy in patients with coronary artery disease: 20 years of follow-up. Circulation. 86(suppl II):1992;II-198-II-204.
14. Nishiyama S, Iwase T, Ishiwata S. Comparison of long-term efficacy of medical treatment versus percutaneous transluminal coronary angioplasty (PTCA) in single vessel disease. Jpn Heart J. 36:1995;565-572.
15. Shepherd J, Cobbe SM, Ford I. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 2335:2335;1001-1009.
16. Downs JR, Clearfield M, Weis S. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 279:1998;1615-1622.
17. Scandinavian Simvastatin, Survival Study. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389.
18. N Engl J Med. 339:1998;1349-1357.
19. Sacks FM, Pfeffer MA, Moye LA, for the Cholesterol and Recurrent Events trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 335:1996;1001-1009.
20. N Engl J Med. 335:1996;217-225.
21. Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet. 348:1996;1079-1082.
22. van Boven AJ, Jukema JW, Zwinderman AH, et al on behalf of the REGRESS study. Reduction of transient myocardial ischemia with pravastatin: addition to the conventional treatment in patients with angina pectoris. Circulation. 94:1996;1503-1505.
23. Davies RF, Goldberg AD, Forman S. Asymptomatic Cardiac Ischemia Pilot (ACIP) study two year follow up: outcomes of patients randomized to initial strategies of medical therapy versus revascularization. Circulation. 95:1997;2037-2043.
24. Falk E, Shah P, Fuster V. Coronary plaque disruption. Circulation. 92:1995;657-671.
25. Fuster V, Badimon L, Badimon JJ. The pathogenesis of coronary disease and acute coronary syndromes. N Engl J Med. 326:1992;242-250.
26. Brown BG, Zhao X, Sacco DE. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation. 87:1993;1781-1791.
27. Ghali JK. Rationale and design of the Myocardial Ischemia Reduction With Aggressive Cholesterol lowering (MIRACL) Study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction. Am J Cardiol. 81:1998;578-581.
28. N Engl J Med. 336:1997;153-162.
29. Kroon AA, Aengevaeren WRM, van der Werf T. The LDL-Apheresis Atherosclerosis Regression Study (LAARS): effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation. 93:1996;1826-1835.